US Representative

Doug Lamborn 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 8)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3462

Introduced
5/18/23  
Empower Parents to Protect Their Kids Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3492

Introduced
5/18/23  
Gun Owner Registration Information Protection Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3520

Introduced
5/18/23  
Refer
5/18/23  
Veteran Care Improvement Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB353

Introduced
1/12/23  
Protect Local Farms Act This bill preempts state laws that provide for a maximum workweek of less than 60 hours for agricultural employees. Under federal law, agricultural employees are generally exempt from maximum hours (i.e., overtime) requirements.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB354

Introduced
1/13/23  
Refer
1/13/23  
Report Pass
5/8/24  
LEOSA Reform Act This bill broadens the authority for certain law enforcement officers to carry concealed firearms across state lines. Specifically, the bill allows qualified active and retired law enforcement officers to carry concealed firearms and ammunition (including magazines) in school zones; in national parks; on state, local, or private property that is open to the public; and in certain federal facilities that are open to the public. Further, the bill permits states to reduce the frequency with which retired law enforcement officers must meet certain qualification standards.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB356

Introduced
1/13/23  
Refer
1/13/23  
Unleashing American Energy Act This bill requires a minimum amount of oil and gas lease sales a year on certain submerged lands of the Outer Continental Shelf (OCS) and limits delays on federal oil and gas leases on such lands. Specifically, this bill requires the Department of the Interior to annually conduct a minimum of two region-wide oil and gas lease sales in each of the following regions of the OCS: (1) the Gulf of Mexico region in the Central Gulf of Mexico Planning Area and the Western Gulf of Mexico Planning Area, and (2) the Alaska region. In addition, the bill requires the President to obtain congressional approval before delaying federal oil and gas leases on the OCS.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3611

Introduced
5/23/23  
Kazakhstan Permanent Normal Trade Relations Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3654

Introduced
5/24/23  
Transnational Repression Policy Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3675

Introduced
5/25/23  
Refer
5/25/23  
Refer
6/9/23  
Western Water Accelerated Revenue Repayment Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3718

Introduced
5/25/23  
Refer
5/25/23  
Department of Veterans Affairs Post-Traumatic Stress Disorder Processing Claims Improvement Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3720

Introduced
5/25/23  
Refer
5/25/23  
HUBS for Veterans Act of 2023 Helping Unleash Benefits and Services for Veterans Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB38

Introduced
1/9/23  
Concealed Carry Reciprocity Act This bill establishes a federal statutory framework to regulate the carry or possession of concealed firearms across state lines. Specifically, an individual who is eligible to carry a concealed firearm in one state may carry or possess a concealed handgun (other than a machine gun or destructive device) in another state that allows its residents to carry concealed firearms. It sets forth requirements for the lawful concealed carry across state lines. The bill preempts most state and local laws related to concealed carry and establishes a private right of action for a person adversely affected by interference with a concealed-carry right established by this bill.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB383

Introduced
1/17/23  
Refer
1/17/23  
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB384

Introduced
1/17/23  
Refer
1/17/23  
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB385

Introduced
1/17/23  
No User Fees for Gun Owners Act This bill prohibits a state or local government from imposing any insurance requirement, tax, user fee, or similar charge as a condition of the manufacture importation, acquisition, transfer, or continued ownership of a firearm or ammunition, with the exception of a proportionate sales tax. The bill imposes the same prohibition under the Internal Revenue Code for firearms, pistols, or revolvers, but allows for the assessment of a proportionate sales tax.